Eli Lilly is spending $3.25 billion to accumulate Kelonia Therapeutics, a small biotech firm growing cell therapies for most cancers and autoimmune ailments, the businesses introduced Monday.
Lilly might pay extra if Kelonia achieves specified scientific, regulatory, and business milestones.
The acquisition is a boon for the small startup, which has subsisted on $60 million during the last 5 years and beforehand struggled to remain afloat. Three instances, the corporate got here inside every week of operating out of money, in response to Bryan Roberts, a accomplice on the enterprise capital agency Venrock, which incubated the biotech.
Following the announcement of Lilly’s acquisition, Roberts shared these anecdotes together with the unique funding memo and slide deck as soon as used to get Kelonia — then referred to as Elcano Therapeutics — off the bottom. The paperwork provide a uncommon have a look at the method of beginning a biotech firm, together with how buyers assessed the “kajillion gene therapy efforts” to deal with.
This article is unique to STAT+ subscribers
Unlock this text — plus each day protection and evaluation of the biotech sector — by subscribing to STAT+.
Already have an account? Log in
To learn the remainder of this story subscribe to STAT+.
